Together, these findings indicate that decreased Erk1/2 phosphorylation in HSP60 KD inhibits cancer cell growth and that OXPHOS inhibitors such as metformin may be used in the treatment of PDAC exhibiting increased Erk1/2 phosphorylation. Here, MAPK3 is linked to cancer.